![](https://cdn.sanity.io/images/0vv8moc6/onclive/3c4f42a486f74343a1dd9e80e5df1f699999dae8-1200x1200.png?fit=crop&auto=format)
Firmonertinib Shows Antitumor Activity in EGFR PACC-Mutated NSCLC
Firmonertinib (AST2818; formerly furmonertinib) demonstrated efficacy and safety in patients with EGFR P-loop and αC-helix compressing(PACC)-mutated non–small cell lung cancer (NSCLC), according to data presented at 2024 World Conference on Lung Cancer.1 “ …